Treatment of anaerobic infection

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 991-1006

  Brook, Itzhak ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaerobes; Antibiotics; Bacteroides; Fusobacterium; Peptostreptococci; Prevotella

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMOXICILLIN PLUS SULBACTAM; AMPICILLIN; AMPICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACITRACIN; BETA LACTAMASE INHIBITOR; CARBENICILLIN; CEFALOTIN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLAVULANIC ACID; CLINDAMYCIN; ERTAPENEM; IMIPENEM; MACROLIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; OXYGEN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TICARCILLIN; TIGECYCLINE; TIMENTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; APLASTIC ANEMIA; ATAXIA; BACTERIAL GROWTH; BACTERIUM ISOLATION; COLITIS; COMBINATION CHEMOTHERAPY; CONVULSION; DEBRIDEMENT; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HUMAN; HYPERBARIC OXYGEN; LEUKOPENIA; MIXED INFECTION; MONOTHERAPY; MUCOSA; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NEWBORN DISEASE; NONHUMAN; OPTIC NEURITIS; OXYGEN THERAPY; PERIPHERAL NEUROPATHY; PHLEBITIS; PUS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SKIN FLORA; SURGICAL DRAINAGE; TASTE DISORDER; TISSUE BLOOD FLOW; TISSUE NECROSIS; TISSUE OXYGENATION; VERTIGO; VOMITING;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BETA-LACTAMASES; CARBAPENEMS; CHLORAMPHENICOL; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; NEGATIVE-PRESSURE WOUND THERAPY; PENICILLINS;

EID: 37449010430     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.991     Document Type: Review

References (111)

1. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 12, 115-121 (2006).
2. Altemeier WA, Fullen WD. Prevention and treatment of gas gangrene. JAMA 217, 806-813 (1971).
3. Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin. Infect. Dis. 15(43), 188-192 (2006).
4. Kindwall EP. Use of hyperbaric oxygen therapy in the 1990s Cleveland clinic. J. Med. 59, 517-528 (1992).
5. Nakajima H, Iwai Y, Yamanaka K, Kishi H. Successful treatment of brainstem abscess with stereotactic aspiration. Surg. Neurol. 52, 445-448 (1999).
6. Pruitt AA. Infections of the nervous system. Neurol. Clin. 16, 419-447 (1998).
7. Brook I, Walker RI. Significance of encapsulated Bacteriodes melaninogenicus and Bacteroides fragilis groups in mixed infections. Infect. Immun. 44, 12-14 (1984).
8. Cinat ME, Wilson SE. New advances in the use of antimicrobial agents in surgery: intra-abdominal infections. J. Chemother. 11, 453-463 (1999).
9. Finegold SM, George WL, Mulligan ME. Anaerobic Infections. Disease a Month (Volume 31). Yearbook Medical Publisher Inc., IL, USA 11-17 (1985).
10. Verklin RM, Mandell GL. Alteration of antibiotics by anaerobiosis. J. Lab. Clin. Med. 89, 65-71 (1977).
11. Gorbach SL, Bartlett JG. Anaerobic infections. N. Engl. J. Med. 290, 1177-1184 (1974).
12. Aldridge KE, Sanders CV. Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole. Anaerobe 8, 301-305 (2002).
13. Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob. Agents Chemother. 10, 736-752 (1976).
14. Brook I, Gober AE. Emergence of β-lactamase-producing aerobic and anaerobic bacteria in the oropharynx of children following penicillin chemotherapy. Clin. Pediatr. 23, 338-342 (1984).
15. Tuner K, Nord CE. Emergence of β-lactamase-producing microorganisms in the tonsils during penicillin treatment. Eur. J. Clin. Microb. 5, 399-404 (1986).
16. Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of B. fragilis group: report and analysis of trends for 1997-2004: a US survey. Antimicrob. Agents Chemother. 1649-1655 (2007).
17. Labbe AC, Bourgault AM, Vincelette J, Turgeon PL, Lamothe F. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob. Agents Chemother. 43, 2517-2519 (1999).
18. Bianchini H, Fernandez Canigia LB, Bantar C, Smayevsky J. Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20-year study at a medical center in Buenos Aires, Argentina. Clin. Infect. Dis. 25, S268-S269 (1997).
19. Garcia-Rodrigues JE, Garcia-Sanchez JE. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain. Clin. Infect. Dis. 12, S142-S151 (1990).
20. Lee KY, Chuong SH, Jeong X-S et al. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea. Clin. Infect. Dis. 23, S73-S77 (1996).
21. Finegold SM. Anaerobic Bacteria in Human Disease. Academic Press, NY, USA (1977).
22. Busch DF, Kureshi LA, Sutter VL, Finegold SM. Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins. Antimicrob. Agents Chemother. 10, 713-720 (1976).
23. Finegold SM. In vitro efficacy of β-lactam/β-lactamase inhibitor combinations against bacteria involved in mixed infections. Int. J. Antimicrob. Agents 12(Suppl. 1), S9-S14 (1999).
24. Acuna C, Rabasseda X. Amoxicillin-sulbactam: a clinical and therapeutic review. Drugs Today (Barcelona) 37, 193-210 (2001).
25. Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to carbenicillin, cefoxitin, and related drugs. J. Infect, Dis. 131, 417-422 (1975).
26. Fiedelman W, Webb CD. Clinical evaluation of carbenicillin in the treatment of infection due to anaerobic bacteria. Curr. Ther. Res. 18, 441-451 (1975).
27. Thadepalli H, Huang JT. Treatment of anaerobic infections: carbenicillin alone compared with clindamycin and gentamicin. Curr. Ther. Res. 22, 549-557 (1977).
28. Brook I. Carbenicillin in treatment of aspiration pneumonia in children. Curr. Ther. Res. 23, 136-147 (1978).
29. Brook I. Anaerobic isolates in chronic recurrent suppurative otitis media: treatment with carbenicillin alone and in combination with gentamicin. Infection 5, 247-251 (1979).
30. Tally FP, Jacobus NV, Bartlett JG, Gorbach SL. In vitro activity of penicillins against anaerobes. Antimicrob. Agents Chemother. 7, 413-414 (1975).
31. Roy I, Bach V, Thadepalli H. In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin. Antimicrob. Agents Chemother. 11, 258-261 (1977).
32. Goldstein EJ, Citron DM, Vaidya SA et al. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. Anaerobe 12, 63-66 (2006).
33. Jousimies H, Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic Gram-negative bacteria (excluding spirochetes). Clin. Infect. Dis. 1 (Suppl. 1), S17-S21 (2002).
34. Jousimies-Somer HR, Summanen P, Baron EJ, Citron DM, Wexler HM, Finegold SM. Wadsworth-KTL Anaerobic Bacteriology Manual (6th Edition). Star Publishing, CA, USA (2002).
35. Brook I. Intra-abdominal, retroperitoneal, and visceral abscesses in children. Eur. J. Pediatr Surg. 14, 265-273 (2004).
36. Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin. Infect. Dis. 35 (Suppl. 1), S106-S111 (2002).
37. Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. 9, 475-488 (2003).
38. Snydman DR, Jacobus NV, McDermott LA et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob. Agents Chemother 43, 2417-2422 (1999).
39. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J. Antimicrob. Chemother. 58, 916-929 (2006).
40. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin. Proc. 74, 420-434 (1999).
41. Edwards JR. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36, 1-17 (1995).
42. Jorgensen JH, Maher LA, Howell AW. Activity of meropenem against antibiotic-resistant or infrequently encountered Gram-negative bacilli. Antimicrob. Agents Chemother. 35, 2410-2414 (1991).
43. Abramowicz M. Meropenem - a new parenteral broad-spectrum antibiotic. Med. Lett. 38, 88-90 (1996).
44. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 65, 2151-2178 (2005).
45. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin. Proc. 74, 825-833 (1999).
46. Thadepalli H, Gorbach SL, Bartlett JG. Apparent failure of chloramphenicol in anaerobic infections. Obstet. Gynecol. Surg. 35, 334-335 (1978).
47. Balbi HJ. Chloramphenicol: a review. Pediatr. Rev. 25, 284-288 (2004).
48. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin. Pharmacokinet. 35, 223-246 (1998).
49. Drutz DJ, Schaffner W, Hillman JW, Koenig MG. The penetration of penicillin and other antimicrobials into joint fluid. J. Bone Joint Surg. 49, 1415-1421 (1967).
50. Joiner KA, Lowe BR, Dzink JL, Bartlett JG. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J. Infect. Dis. 143, 487-494 (1981).
51. Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared with those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob. Agent Chemother. 43, 1469-1474 (1999).
52. Williams JD, Maskell JP, Shain H et al. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J. Antimirob. Chemother. 30, 27-37 (1992).
53. Sanai Y, Persson GR, Starr JR et al. Presence and antibiotic resistance of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens in children. J. Clin. Periodontol. 29, 929-934 (2002).
54. Finegold SM, Harada NE, Miller LG. Lincomycin activity against anaerobes and effect on normal human fecal flora. Antimicrob. Agents Chemother. 5, 659-667 (1965).
55. Klainer AS. Clindamycin. Med. Clin. North Am. 71, 1169-1175 (1987).
56. LeFrock JL, Molavi A, Prince RA. Clindamycin. Med. Clin. North Am. 66, 103-120 (1982).
57. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin. Pharmacokinet. 19, 280-318 (1990).
58. Feigin RD, Pickering LK, Anderson D, Keeney RE, Shackleford PG. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics 55, 213-223 (1975).
59. Novak E, Wagner JG, Lamb DJ. Local and systemic tolerance, absorption and excretion of clindamycin hydrochloride after intramuscular administration. Int. Z. Klin. Pharmakol. Ther. Toxikol. 3, 201-208 (1970).
60. Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J. Clin. Pharmacol. 12, 259-262 (1972).
61. Gorbach SL, Thadepalli H. Clindamycin in the treatment of pure and mixed anaerobic infections. Arch. Intern. Med. 134, 87-92 (1974).
62. Gorbach SL. Antibiotics and Clostridium difficile. N. Engl. J. Med. 341, 1690-1691 (1999).
63. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficite - associated diarrhea: a review. Arch. Intern. Med. 161, 525-533 (2001).
64. Devenyi AG. Antibiotic-induced colitis. Semin. Pediatr. Surg. 4, 215-220 (1995).
65. Berlatzky Y, Rubin SZ, Michel J, Sacks T, Schiller M. Use of clindamycin and gentamicin in pediatric colonic surgery. J. Pediatr. Surg. 11, 83-94 (1976).
66. Brook I. Clindamycin in treatment of aspiration pneumonia in children. Antimicrob. Agents Chemother. 15, 342-344 (1979).
67. Brook I. Bacteriology and treatment of chronic otitis media in children. Laryngoscope 89, 1129-1134 (1979).
68. Brook I. Yocum P. Antimicrobial management of chronic sinusitis in children. J. Laryngol. Otol. 109, 1159-1162 (1995).
69. Brook I, Lewis MA, Sandor GK, Jeffcoat M, Samaranayake LP, Vera Rojas J. Clindamycin in dentistry: more than just effective prophylaxis for endocarditis? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100, 550-558 (2005).
70. Chow AW, Patten V, Guze LB. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of nonspore forming Gram-positive bacilli. J. Infect. Dis. 131, 182-185 (1975).
71. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 54, 679-708 (1997).
72. Rustia M, Shubik F. Experimental induction of hematomas, mammary tumors and other tumors with metronidazole in noninbred Sas: WRC (WT) BR rats. J. Natl Cancer Instit. 63, 863-868 (1979).
73. Cohen SM, Erturk E, Von Esch AM, Crovetti AJ, Bryan GT. Carcinogenicity of 5-nitro-furans 5-nitromidazoles, 4-nitrobenzenes and related compounds. J. Natl Cancer Instit. 51, 403-417 (1973).
74. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N. Engl. J. Med. 301, 519-522 (1979).
75. Tany FP, Gorbach SL. Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis. Am. J. Med. 7(78), 145-153 (1985).
76. Berman BW, King FH Jr, Rubenstein DS, Long SS. Bacteroides fragilis meningitis in a neonatal successfully treated with metronidazole. J. Pediatr. 93, 793-795 (1979).
77. Sørensen HT, Larsen H, Jensen ES et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J. Antimicrob. Chemother. 44, 854-855 (1999).
78. Brook I. Treatment of anaerobic infections in children with metronidazole. Dev. Pharmacol. 6, 187-198 (1983).
79. Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int. J. Clin. Pract. 60(12), 1662-1672 (2006).
80. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob. Agents Chemother. 50, 3507-3513 (2006).
81. Appelbaum PC. Quinolone activity against anaerobes. Drugs 58, 60-64 (1999).
82. Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin. Infect. Dis. 42, 1598-1607 (2006).
83. Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 51, 31-37 (1996).
84. Brook I. Pathogenicity and management of polymicrobial infections due to aerobic and anaerobic bacteria. Med. Res. Rev. 15, 73-82 (1995).
85. Bartlett JG. Recent developments in the management of anaerobic infection. Rev. Inf. Dis. 5, 235-245 (1983).
86. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections - a review on randomised clinical trials. Eur. J. Med. Res. 30(6), 277-291 (2001).
87. Tenado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg. Infect. (Larchmt) 6, 329-333 (2005).
88. Sanabria A. Decision-making analysis for selection of antibiotic treatment in intra-abdominal infection using preference measurements. Surg. Infect. (Larchmt) 7, 453-462 (2006).
89. Laterre PF, Colardyn F, Delmee M et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB). Acta Chir Belg. 106, 2-21 (2006).
90. Marshall JC. Intra-abdominal infections. Microbes Infect. 6, 1015-1025 (2004).
91. Giamarellou H, Kanellakopoulou K. Bacteriologic and therapeutic considerations in intra-abdominal surgical infections. Anaerobe 3, 207-212 (1997).
92. Verwaest C: Belgian Multicenter Study Group. Meropenem versus imipenem/ cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin. Microbiol. Infect. 6, 294-302 (2000).
93. Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin. Pharmacother. 8, 237-256 (2007).
94. Munckhof WJ, Carney I Neilson G et al. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents 25, 514-522 (2005).
95. Powell LL, Wilson SE. The role of β-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg. Infect. (Larchmt) 1, 57-63 (2000).
96. Brook I, Coolbaugh JC, Walker RI, Weiss E. Synergism between penicillin, clindamycin or metronidazole and gentamicin against species of Bacteroides melaninogenicus and fragilis groups. Antimicrob. Agents Chemother. 25, 71-77 (1984).
97. Acar JF. Antibiotic synergy and antagonism. Med. Clin. North Am. 84, 1391-1406 (2000).
98. Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. 35 (Suppl. 1), S126-S134 (2002).
99. Bergan T, Fotland MH. In vitro interactions between metronidazole or tinidazole and co-trimoxazole on the effect against anaerobic bacteria. Scand. J. Gastroenterology 19(Suppl.) 95 (1984).
100. Ralph ED, Amatnieks YE. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob. Agents Chemother. 17, 379 (1980).
101. Busch DF, Sutter VL, Finegold SM. Activity of combinations of antimicrobial agents against Bacteroides fragilis. J. Infect. Dis. 133, 321-328 (1976).
102. Brook I. Metronidazole and spiramycin in abscesses caused by Bacteroides spp. Staphylococcus aureus in mice. J. Antimicrob. Chemother. 20, 713-718 (1987).
103. Videau D, Blanchard JC, Sebald M. Bucco-dental flora. Sensitivity to antibiotics and value of the spiramycin-metronidazole combination. Ann. Microbiol. 1248, 505-516 (1973).
104. Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J. Antimicrob. Chemother. 45, 633-638 (2000).
105. Credito KL, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn. Microbiol. Infect. Dis. 38, 181-183 (2000).
106. Fass RJ, Rotilie CA, Prior RB. Interaction of clindamycin and gentamicin in vitro. Antimicrob. Agents Chemother. 6, 582-587 (1974).
107. Okubadejo OA, Allen J. Combined activity of clindamycin and gentamicin on Bacteroides fragilis and other bacteria. J. Antimicrob. Chemother. 1, 403-409 (1975).
108. Brook I, Walker RI. Interaction between penicillin, clindamycin or metronidazole and gentamicin against species of clostridia and anaerobic and facultative anaerobic Gram-positive cocci. J. Antimicrob. Chemother. 15, 31-37 (1985).
109. Bryan LE, Kowand SK, Den Elzen HM. Mechanisms of aminoglycoside antibiotic resistance in anaerobic bacteria: Clostridium perfringens and Bacteroides fragilis. Antimicrob. Agents Chemother. 15, 7-13 (1979).
110. Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin. Infect. Dis. 44, 895-900 (2007).
111. Nguyen MH, Yu VL, Morris AJ et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30, 870-876 (2000).